SK2902003A3 - Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof - Google Patents

Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof Download PDF

Info

Publication number: SK2902003A3
Authority: SK; Slovakia
Prior art keywords: fluoroanilino; chloro; methyl; phenylacetic acid; pharmaceutically acceptable
Prior art date: 2000-09-11

Application number

SK290-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Simon David Bateman

Alberto Gimona

Jurij Holinej

Jasper Huels

Sumedha Jayawardene

Argeris Jerry Karabelas

Maha Y Khaled

Anees Abdulquadar Karnachi

Lochlainn Eimear Mairin Nic

Richard Macerata

Victor Sloan

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-11

Filing date

2001-09-10

Publication date

2003-10-07

2001-09-10 Application filed by Novartis Ag filed Critical Novartis Ag

2003-10-07 Publication of SK2902003A3 publication Critical patent/SK2902003A3/sk

Links

KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 title claims abstract description 55
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
150000003839 salts Chemical class 0.000 title claims abstract description 24
239000000203 mixture Substances 0.000 claims abstract description 105
239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 31
108010037462 Cyclooxygenase 2 Proteins 0.000 claims abstract description 20
238000011282 treatment Methods 0.000 claims abstract description 15
230000001419 dependent effect Effects 0.000 claims abstract description 8
102000010907 Cyclooxygenase 2 Human genes 0.000 claims abstract 3
239000004480 active ingredient Substances 0.000 claims description 49
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 22
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 18
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 18
229920002785 Croscarmellose sodium Polymers 0.000 claims description 17
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 17
229960001681 croscarmellose sodium Drugs 0.000 claims description 16
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 16
238000000034 method Methods 0.000 claims description 16
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 15
229940069328 povidone Drugs 0.000 claims description 15
238000013268 sustained release Methods 0.000 claims description 15
239000012730 sustained-release form Substances 0.000 claims description 15
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
239000008108 microcrystalline cellulose Substances 0.000 claims description 13
229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 11
235000019359 magnesium stearate Nutrition 0.000 claims description 11
239000004408 titanium dioxide Substances 0.000 claims description 11
-1 5- methyl 2- (2'-chloro-6'-fluoroanilino) benzyl Chemical group 0.000 claims description 6
235000019445 benzyl alcohol Nutrition 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
229960001375 lactose Drugs 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 4
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 2
229960001021 lactose monohydrate Drugs 0.000 claims description 2
229960005196 titanium dioxide Drugs 0.000 claims description 2
235000010215 titanium dioxide Nutrition 0.000 claims description 2
229940057948 magnesium stearate Drugs 0.000 claims 1
239000003826 tablet Substances 0.000 description 51
238000009472 formulation Methods 0.000 description 43
239000013543 active substance Substances 0.000 description 34
238000007906 compression Methods 0.000 description 23
230000006835 compression Effects 0.000 description 23
238000000576 coating method Methods 0.000 description 21
239000011248 coating agent Substances 0.000 description 20
239000008187 granular material Substances 0.000 description 20
230000002354 daily effect Effects 0.000 description 18
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
238000004090 dissolution Methods 0.000 description 15
150000001875 compounds Chemical class 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
239000002245 particle Substances 0.000 description 13
208000002193 Pain Diseases 0.000 description 12
238000005469 granulation Methods 0.000 description 12
230000003179 granulation Effects 0.000 description 12
230000000694 effects Effects 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
239000011230 binding agent Substances 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
210000002381 plasma Anatomy 0.000 description 9
239000000725 suspension Substances 0.000 description 9
239000007884 disintegrant Substances 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
239000000314 lubricant Substances 0.000 description 8
239000000902 placebo Substances 0.000 description 8
229940068196 placebo Drugs 0.000 description 8
239000008213 purified water Substances 0.000 description 8
230000004044 response Effects 0.000 description 8
239000001993 wax Substances 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
238000009478 high shear granulation Methods 0.000 description 7
230000036470 plasma concentration Effects 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
239000002552 dosage form Substances 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
239000012528 membrane Substances 0.000 description 6
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
201000008482 osteoarthritis Diseases 0.000 description 6
230000008569 process Effects 0.000 description 6
239000007921 spray Substances 0.000 description 6
239000002253 acid Substances 0.000 description 5
238000004040 coloring Methods 0.000 description 5
229960001259 diclofenac Drugs 0.000 description 5
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 5
201000010099 disease Diseases 0.000 description 5
239000000945 filler Substances 0.000 description 5
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 5
108010037464 Cyclooxygenase 1 Proteins 0.000 description 4
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
239000003094 microcapsule Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
238000000465 moulding Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
239000007916 tablet composition Substances 0.000 description 4
230000009471 action Effects 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000008279 sol Substances 0.000 description 3
LMPXSEKGZZVPNI-UHFFFAOYSA-N 2-(2-chloro-6-fluoroanilino)-5-methylbenzoic acid Chemical compound OC(=O)C1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl LMPXSEKGZZVPNI-UHFFFAOYSA-N 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
208000007882 Gastritis Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
208000007353 Hip Osteoarthritis Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000003947 Knee Osteoarthritis Diseases 0.000 description 2
101100504379 Mus musculus Gfral gene Proteins 0.000 description 2
229920003081 Povidone K 30 Polymers 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000001816 cooling Methods 0.000 description 2
229960005168 croscarmellose Drugs 0.000 description 2
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
229940079593 drug Drugs 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
238000003475 lamination Methods 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
238000005457 optimization Methods 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
230000003349 osteoarthritic effect Effects 0.000 description 2
229960003424 phenylacetic acid Drugs 0.000 description 2
239000003279 phenylacetic acid Substances 0.000 description 2
239000000049 pigment Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000003825 pressing Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
206010006811 Bursitis Diseases 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000033131 Congenital factor II deficiency Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000007646 Hypoprothrombinemias Diseases 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
206010028836 Neck pain Diseases 0.000 description 1
102000007530 Neurofibromin 1 Human genes 0.000 description 1
108010085793 Neurofibromin 1 Proteins 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
208000010040 Sprains and Strains Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046809 Uterine pain Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000005354 coacervation Methods 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
238000001246 colloidal dispersion Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
208000007784 diverticulitis Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
239000004519 grease Substances 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
NXMXPVQZFYYPGD-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;methyl prop-2-enoate Chemical compound COC(=O)C=C.COC(=O)C(C)=C NXMXPVQZFYYPGD-UHFFFAOYSA-N 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920002959 polymer blend Polymers 0.000 description 1
229920005597 polymer membrane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
201000007183 prothrombin deficiency Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000012925 reference material Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
208000004371 toothache Diseases 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
229920003176 water-insoluble polymer Polymers 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK290-2003A 2000-09-11 2001-09-10 Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof SK2902003A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US23165500P	2000-09-11	2000-09-11
US23226100P	2000-09-14	2000-09-14
PCT/EP2001/010448 WO2002020090A2 (en)	2000-09-11	2001-09-10	Pharmaceutical compositions

Publications (1)

Publication Number	Publication Date
SK2902003A3 true SK2902003A3 (en)	2003-10-07

Family

ID=26925315

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK290-2003A SK2902003A3 (en)	2000-09-11	2001-09-10	Pharmaceutical compositions comprising 5-methyl-2(2'-chloro-6'- fluoroanilino) phenylacetic acid or a pharmaceutically acceptable salt thereof

Country Status (28)

Country	Link
US (2)	US20020061932A1 (de)
EP (1)	EP1331972B1 (de)
JP (2)	JP2004527458A (de)
KR (1)	KR20030036730A (de)
CN (1)	CN100490797C (de)
AR (1)	AR030630A1 (de)
AT (1)	ATE366128T1 (de)
AU (2)	AU2002213900C1 (de)
BR (1)	BR0113809A (de)
CA (1)	CA2416771C (de)
CY (1)	CY1107729T1 (de)
CZ (1)	CZ2003673A3 (de)
DE (1)	DE60129238T2 (de)
DK (1)	DK1331972T3 (de)
ES (1)	ES2290181T3 (de)
HU (1)	HUP0301128A3 (de)
IL (2)	IL154238A0 (de)
MX (1)	MXPA03002105A (de)
MY (1)	MY126117A (de)
NO (1)	NO20031095L (de)
NZ (1)	NZ524785A (de)
PE (1)	PE20020351A1 (de)
PL (1)	PL359721A1 (de)
PT (1)	PT1331972E (de)
RU (1)	RU2316324C2 (de)
SI (1)	SI1331972T1 (de)
SK (1)	SK2902003A3 (de)
WO (1)	WO2002020090A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20030323A1 (es) *	2001-08-31	2003-05-12	Novartis Ag	Composicion farmaceutica
GB0201520D0 (en) *	2002-01-23	2002-03-13	Novartis Ag	Pharmaceutical uses
RU2318497C2 (ru) *	2002-03-07	2008-03-10	Новартис Аг	Фармацевтические композиции
US7220749B2 (en)	2002-06-11	2007-05-22	Nitromed, Inc.	Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
AR042206A1 (es)	2002-11-26	2005-06-15	Novartis Ag	Acidos fenilaceticos y derivados
TWI327913B (en) *	2003-03-12	2010-08-01	Novartis Ag	Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid
US20050131028A1 (en) *	2003-09-11	2005-06-16	Pharmacia Corporation	Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
RU2423979C2 (ru) *	2005-06-17	2011-07-20	АФТ Фармасьютикалз Лимитед	Новая фармацевтическая композиция и ее применение в способе лечения пациентов с гиперемией и отеком слизистой оболочки верхних дыхательных путей
FR2898492B1 (fr) *	2006-03-15	2008-06-06	Pierre Fabre Medicament Sa	Comprimes orodispersibles de domperidone
EP2043613A1 (de) *	2006-07-14	2009-04-08	Fmc Corporation	Feste form
WO2008086530A2 (en) *	2007-01-11	2008-07-17	Analog Devices, Inc.	Mems sensor with cap electrode
WO2010022211A1 (en) *	2008-08-22	2010-02-25	Novartis Ag	Use of a cox-2 inhibitor for the treatment of a cox-2 dependent disorder in a patient not carrying hla alleles associated with hepatotoxicity
WO2010056741A2 (en)	2008-11-12	2010-05-20	Auspex Pharmaceuticals, Inc.	Phenylacetic acid inhibitors of cyclooxygenase
CN103773596B (zh) *	2013-12-31	2016-05-18	上海复力生物医药科技有限公司	磷虾油的制备方法
WO2018049027A1 (en)	2016-09-07	2018-03-15	Trustees Of Tufts College	Combination therapies using immuno-dash inhibitors and pge2 antagonists
CN111278433A (zh)	2017-09-26	2020-06-12	特沙诺有限公司	尼拉帕尼制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ267417A (en) *	1993-06-08	1997-02-24	Ciba Geigy Ag	An inclusion compound of diclofenac and gamma-cyclodextrin and compressed dosage forms thereof
US5474995A (en) *	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
AU3004997A (en) *	1996-05-17	1997-12-09	Merck & Co., Inc.	Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
CO4960662A1 (es) *	1997-08-28	2000-09-25	Novartis Ag	Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
SA99191255B1 (ar) *	1998-11-30	2006-11-25	جي دي سيرل اند كو	مركبات سيليكوكسيب celecoxib
PE20030323A1 (es) *	2001-08-31	2003-05-12	Novartis Ag	Composicion farmaceutica

2001
- 2001-09-07 AR ARP010104260A patent/AR030630A1/es unknown
- 2001-09-07 PE PE2001000900A patent/PE20020351A1/es not_active Application Discontinuation
- 2001-09-10 MY MYPI20014237A patent/MY126117A/en unknown
- 2001-09-10 CZ CZ2003673A patent/CZ2003673A3/cs unknown
- 2001-09-10 AT AT01982270T patent/ATE366128T1/de active
- 2001-09-10 RU RU2003109606/15A patent/RU2316324C2/ru not_active IP Right Cessation
- 2001-09-10 HU HU0301128A patent/HUP0301128A3/hu unknown
- 2001-09-10 WO PCT/EP2001/010448 patent/WO2002020090A2/en not_active Ceased
- 2001-09-10 PT PT01982270T patent/PT1331972E/pt unknown
- 2001-09-10 ES ES01982270T patent/ES2290181T3/es not_active Expired - Lifetime
- 2001-09-10 PL PL35972101A patent/PL359721A1/xx not_active Application Discontinuation
- 2001-09-10 MX MXPA03002105A patent/MXPA03002105A/es active IP Right Grant
- 2001-09-10 NZ NZ524785A patent/NZ524785A/en unknown
- 2001-09-10 IL IL15423801A patent/IL154238A0/xx active IP Right Grant
- 2001-09-10 SI SI200130773T patent/SI1331972T1/sl unknown
- 2001-09-10 KR KR10-2003-7002711A patent/KR20030036730A/ko not_active Ceased
- 2001-09-10 JP JP2002524572A patent/JP2004527458A/ja not_active Withdrawn
- 2001-09-10 DE DE60129238T patent/DE60129238T2/de not_active Expired - Lifetime
- 2001-09-10 EP EP01982270A patent/EP1331972B1/de not_active Expired - Lifetime
- 2001-09-10 AU AU2002213900A patent/AU2002213900C1/en not_active Ceased
- 2001-09-10 CN CNB018154549A patent/CN100490797C/zh not_active Expired - Fee Related
- 2001-09-10 SK SK290-2003A patent/SK2902003A3/sk unknown
- 2001-09-10 BR BR0113809-0A patent/BR0113809A/pt not_active Application Discontinuation
- 2001-09-10 DK DK01982270T patent/DK1331972T3/da active
- 2001-09-10 AU AU1390002A patent/AU1390002A/xx active Pending
- 2001-09-10 CA CA2416771A patent/CA2416771C/en not_active Expired - Fee Related
- 2001-09-11 US US09/950,538 patent/US20020061932A1/en not_active Abandoned
2003
- 2003-01-30 IL IL154238A patent/IL154238A/en not_active IP Right Cessation
- 2003-03-10 NO NO20031095A patent/NO20031095L/no not_active Application Discontinuation
2004
- 2004-03-24 US US10/807,734 patent/US20040186179A1/en not_active Abandoned
2007
- 2007-09-07 CY CY20071101157T patent/CY1107729T1/el unknown
2011
- 2011-03-09 JP JP2011051754A patent/JP2011144194A/ja active Pending

Also Published As

Publication number	Publication date
DE60129238T2 (de)	2008-03-06
ES2290181T3 (es)	2008-02-16
EP1331972B1 (de)	2007-07-04
MXPA03002105A (es)	2003-06-19
WO2002020090A3 (en)	2003-05-30
KR20030036730A (ko)	2003-05-09
MY126117A (en)	2006-09-29
NO20031095D0 (no)	2003-03-10
RU2316324C2 (ru)	2008-02-10
WO2002020090A2 (en)	2002-03-14
CA2416771A1 (en)	2002-03-14
EP1331972A2 (de)	2003-08-06
AU2002213900B2 (en)	2006-02-16
US20020061932A1 (en)	2002-05-23
CN100490797C (zh)	2009-05-27
BR0113809A (pt)	2003-07-29
CN1455691A (zh)	2003-11-12
DK1331972T3 (da)	2007-11-05
AU2002213900C1 (en)	2006-07-27
ATE366128T1 (de)	2007-07-15
CY1107729T1 (el)	2013-04-18
JP2004527458A (ja)	2004-09-09
AU1390002A (en)	2002-03-22
HUP0301128A2 (hu)	2003-10-28
WO2002020090A9 (en)	2003-10-30
US20040186179A1 (en)	2004-09-23
CZ2003673A3 (cs)	2003-06-18
DE60129238D1 (de)	2007-08-16
HUP0301128A3 (en)	2005-04-28
CA2416771C (en)	2010-11-02
PE20020351A1 (es)	2002-06-14
PT1331972E (pt)	2007-10-16
NO20031095L (no)	2003-03-10
NZ524785A (en)	2005-10-28
AR030630A1 (es)	2003-08-27
SI1331972T1 (sl)	2007-12-31
PL359721A1 (en)	2004-09-06
IL154238A0 (en)	2003-09-17
IL154238A (en)	2008-11-26
JP2011144194A (ja)	2011-07-28

Legal Events

Date	Code	Title	Description
2012-04-03	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
US20070231382A1 (en)	2007-10-04	Pharmaceutical composition
JP2011144194A (ja)	2011-07-28	医薬組成物
AU2002331094A1 (en)	2003-06-05	Pharmaceutical composition comprising lumiracoxib
AU2002213900A1 (en)	2002-06-13	Pharmaceutical compositions
JP2004527458A5 (de)	2008-10-30
CA3001288C (en)	2022-07-19	Modified release formulation of naproxen sodium
US20090149543A1 (en)	2009-06-11	Solid pharmaceutical compositions comprising lumiracoxib
ZA200300555B (en)	2004-03-31	Pharmaceutical compositions.
HK1087336B (en)	2009-07-03	Pharmaceutical composition comprising lumiracoxib
HK1057344A (en)	2004-04-02	Pharmaceutical compositions